Summary
- Edinburgh-based 1nhaler has secured £2.2m in follow-on funding.
- The round was led by Archangels with support from Scottish Enterprise and BBB Investments.
- The money will fund late-stage development of its lead product, 1nhaler Salbutamol.
- It will also support a small clinical trial, with regulatory filing targeted for late 2027.
- The single-dose inhaler is made predominantly from cardboard and is the size and shape of a credit card.
Full Article
Edinburgh-based drug delivery device developer 1nhaler has secured £2.2m in follow-on funding to progress its pop-up cardboard inhaler towards first regulatory approval.
The round was led by Archangels with support from Scottish Enterprise and BBB Investments.
The investment will fund late-stage development of the company’s lead product, 1nhaler Salbutamol, which combines its device with salbutamol, a well-established asthma medicine. It will complete the transfer of the product into contract manufacturing to produce clinical trial material and progress a small clinical trial to support a regulatory filing targeted for late 2027.
The funding will also support a manufacturing engineering study with Harro Höfliger for commercial scale-up of the dry powder inhaler.
The single-dose inhaler is made predominantly from cardboard and is the size and shape of a credit card. It transforms into a three-dimensional inhaler for patient use and has few components, including a patent-protected membrane-based system. The company says it is designed to be simpler and more affordable to manufacture at scale, and that the platform could deliver dry powder medicines for other uses, including pain relief and vaccines.
Lisa McMyn, co-founder and chief executive, said: “This investment takes us to one of the most important milestones in our journey – taking our own lead product into the clinic. The continued backing of Archangels, Scottish Enterprise and BBB Investments reflects the technical and commercial progress we have made over the past year.”
Dr Sarah Hardy, director and head of new investments at Archangels, said: “Having backed 1nhaler since 2023, we see this latest round as a reflection of our confidence in the team and its novel inhaler device that has the potential to disrupt the global market for inhaled medicines.
“We are particularly excited by the commercial traction and interest from potential partners across a broader range of drugs than we initially anticipated, highlighting the platform’s versatility and market potential.”
In Case You Missed It:
EnteroBiotix appoints former GSK chief medical officer to board as IBS-C trial progresses
Singular Photonics raises $2.15m and says it has doubled sales and is nearing break-even
Genel raises offer for Edinburgh-based Capricorn Energy to top DNO bid
Hymans Robertson partners with Heka to strengthen pension data tracing
Derek Shaw, director of company funding and investment at Scottish Enterprise, said: “This investment highlights our dedication to supporting the growth of ambitious businesses in Scotland.”
The company was founded by Don Smith and Lisa McMyn. Its team includes chief scientific officer Helen Muirhead, former head of GSK’s Respiratory Centre of Excellence, and chief medical officer Lars Larsson, formerly medical director, licensing, at AstraZeneca.
